MRTX Projected Dividend Yield
Mirati Therapeutics Inc ( NASDAQ : MRTX )Mirati Therapeutics is a clinical-stage oncology company developing therapeutics to address the genetic and immunological promoters of cancer. Co.'s product candidates include: Adagrasib, an investigational, selective, specific, potent and orally available KRAS G12C inhibitor in clinical development as a monotherapy and in combination with other agents; MRTX1133, an investigational, selective, specific and potent KRAS G12D inhibitor in preclinical development; Sitravatinib, an investigational spectrum-selective kinase inhibitor; and MRTX1719, an internally discovered investigational synthetic lethal PRMT5 inhibitor to target the PRMT5/methylthioadensoine complex in preclinical development. 20 YEAR PERFORMANCE RESULTS |
MRTX Dividend History Detail MRTX Dividend News MRTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |